Any feedback?
Please rate this page
(all_enzymes.php)
(0/150)

BRENDA support

1.14.11.68: [histone H3]-trimethyl-L-lysine27 demethylase

This is an abbreviated version!
For detailed information about [histone H3]-trimethyl-L-lysine27 demethylase, go to the full flat file.

Word Map on EC 1.14.11.68

Reaction

a [histone H3]-N6,N6,N6-trimethyl-L-lysine27
+ 2 2-oxoglutarate + 2 O2 =
a [histone H3]-N6-methyl-L-lysine27
+ 2 succinate + 2 formaldehyde + 2 CO2

Synonyms

F18E9.5, histone demethylase, jmjd-3.1, JMJD3, KDM6A, Kdm6al, KDM6B, KDM6C, lysine-specific demethylase 6A, lysine-specific demethylase 6B, UTX, UTX1, UTY

ECTree

     1 Oxidoreductases
         1.14 Acting on paired donors, with incorporation or reduction of molecular oxygen
             1.14.11 With 2-oxoglutarate as one donor, and incorporation of one atom of oxygen into each donor
                1.14.11.68 [histone H3]-trimethyl-L-lysine27 demethylase

Inhibitors

Inhibitors on EC 1.14.11.68 - [histone H3]-trimethyl-L-lysine27 demethylase

Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
GSK-J4
GSKJ4
inhibitor is active against native and temozolomide-resistant glioblastoma cells, albeit at at a lower effcacy than JIB 04, inhibitor of lysine demethylase KDM5A, EC 1.14.11.67. GSK J4 and JIB 04 strongly synergize and are a potent combination against temozolomide-resistant glioblastoma cells. GSK J4 does not synergize with temozolomide
-